



# महामना पंडित मदन मोहन मालवीय कैंसर केंद्र एवं होमी भाभा कैंसर अस्पताल MAHAMANA PANDIT MADAN MOHAN MALAVIYA CANCER CENTRE & HOMI BHABHA CANCER HOSPITAL

(टाटा स्मारक केंद्र की इकाईयां / Units of TATA MEMORIAL CENTRE) परमाणु ऊर्जा विभाग, भारत सरकार / DEPT. OF ATOMIC ENERGY, GOVT. OF INDIA वाराणसी, उत्तर प्रदेश — २२१००५ / VARANASI, UTTAR PRADESH — 221005



Date: 30.04.2025

Ref. No. HBCH/MPMMCC/PROJECT/2025/23

# WALK-IN INTERVIEW for PROJECT VACANCIES on Wednesday,09th May 2025 between 09:00 A.M. TO 10:00 A.M.

### Job Location: HOMI BHABHA CANCER HOSPITAL & MAHAMANA PANDIT MADAN MOHAN MALVIYA CANCER CENTRE, VARANASI

Sr. No.	Post Name	Project Name & A/c No.	No. of post	Eligibility Criteria	Monthly Remuneration (in Rs.)	Walk-In Interview on
1.	Research Assistant	Evaluation Of Quality of Life In Segmental Mandibulectomy Patients Using Mandibular Guidance application and a proposed Oral Rehabilitation Questionnaire for Mandibular guidance appliance- A Prospective Observational Study: A/c No. 9299	01	Graduate degree in science from a recognized University with Computer Course of minimum 3 months duration in Microsoft Office alongwith	Rs. 23,000/-	Tuesday, 06.05.2025
2.	Research Assistant	A randomized, open-label, double arm, phase III study of doublet vs monotherapy in advanced pancreatic cancer who have failed-line therapy: A/c No. <b>9299</b>	01	minimum six months experience in assisting clinical research project in an		
3.	Research Assistant	Upfront surgery followed by adjuvant treatment versus chemoradiotherapy (CCRT) in Head and Neck Squamous cell carcinoma of Unknown Primary with neck node metastasis: A Phase III randomized controlled trial Study Code (SCCoUP Trial): A/c No. 9299	01	Institution.		
4.	Data Entry Operator	A Phase III, Two–arm, Parallel, Randomized, Multi-Centre, Open-Label, Globel Study to Determine the efficacy of Volrustoming (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) (eVOLVE-Lung02): A/c No. 9404	01	Graduate from a recognized University with 01-year relevant work experience. Computer course of minimum 06 months.	Rs. 19,000/- to Rs. 21,000/-	
5.	Medical Social Worker	late area of Courses have in a Pallinting Course A / A No. 2455	01	Post Graduate Degree in Social Sciences (MSW) from a recognized University with minimum one year experience after MSW in the field of Medical Social work.	Rs. 25,000/-	Wednesday, 07.05.2025
6.	Clinical Psychologist	Integrated Comprehensive Palliative Care: A/c No. 9455	01	M.A / M. Phill. In Clinical Psychology / General Psychology with minimum 01-year clinical experience.	Rs. 25,000/- to Rs. 30,000/-	-
				Any Fellowship in Clinical Psychology / Ph.D. is desirable		
7.	Medical Officer	The efficacy of conventional screening versus mHealth screening in early detection of oral potentially malignant disorders and oral cancer amongst the rural population of Varanasi: A Prospective and blinded study: A/c No. 9276	01	Candidate having MD / MDS Degree and experience in Public Health / Outreach cancer screening will be preferred.	Rs. 30,000/- to Rs. 40,000/-	Thursday, 08.05.2025
8.	Clinical Trial Coordinator	KontRASt-06: An open-label phase II trial evaluating the activity and safety of JDQ443 single agent as first-line treatment for patients with locally advanced or metastatic KRAS G12Cmutated non-small cell lung cancer: A/c No. 9233	01	Graduate degree in science with PG Diploma in Clinical Research is mandatory. Experience of one year in relevant experience is	Rs. 25,000/- to Rs. 30,000/-	
9.	Clinical Trial Coordinator	PACIFIC-08: A phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose disease has not progressed following definitive Platinum-based Concurrent Chemo radiation Therapy: A/c No. 160009	01	desirable.		Friday, 09.05.2025
10.	Clinical Trial Coordinator	Study Code D9673L00012: A Prospective, Multi-Center, Phase 4, Single Arm Study to assess the safety of Transtuzumab Deruxtecan, an Anti-her2-antibody drug conjugate in Indian patients with unresectable or metastatic her2-based regimen: A/c No. 180003	01			





# महामना पंडित मदन मोहन मालवीय कैंसर केंद्र एवं होमी भाभा कैंसर अस्पताल MAHAMANA PANDIT MADAN MOHAN MALAVIYA CANCER CENTRE & HOMI BHABHA CANCER HOSPITAL

(टाटा स्मारक केंद्र की इकाईयां / Units of TATA MEMORIAL CENTRE) परमाणु ऊर्जा विभाग, |भारत सरकार / DEPT. OF ATOMIC ENERGY, GOVT. OF INDIA वाराणसी, उत्तर प्रदेश — २२१००५ / VARANASI, UTTAR PRADESH — 221005



\*The tenure will be valid for initial period of six months, further extendable, if required, subject to satisfactory performance.

The candidates are required to carry their bio-data, recent passport size photograph, PAN card, Aadhar card, educational and experience certificates in Original and one set of self-attested copies on given date for attending interview at <a href="Mahamana Pandit Madan Mohan Malaviya Cancer Centre">Mahamana Pandit Madan Mohan Malaviya Cancer Centre</a>, <a href="Sunder Bagiya">Sunder Bagiya</a>, BHU Campus, Varanasi, Uttar Pradesh -221005, Phone No. 0542-25176700

In case of more candidates, MCQ Test will be conducted and eligible candidates will be shortlisted for the interview, accordingly.

#### Note:

For post(s) at S.N. 05, 06, 08, 09 & 10, the outstation candidate(s) will have the option of attending the Interview Online. For the purpose, candidate(s) will be required to send their resume alongwith the supporting documents in a single PDF file at <a href="recruitment@mpmmcc.tmc.gov.in">recruitment@mpmmcc.tmc.gov.in</a> on or before 05.05.2025, while mentioning the advertisement number and post applied for in subject line of the email. Only Shortlisted Candidates who will be fulfilling the eligibility norms will be contacted for Online Interview.

(PIYUSH TRIPATHI)
ADMINISTRATIVE OFFICER III (HRD)